ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Shorted: Short Interest Up 52.5% in October

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report) saw a large growth in short interest in October. As of October 30th, there was short interest totaling 10,116 shares, a growth of 52.5% from the October 15th total of 6,632 shares. Based on an average daily trading volume, of 9,215 shares, the days-to-cover ratio is currently 1.1 days. Approximately 1.2% of the company’s shares are sold short.

ProShares Ultra Nasdaq Biotechnology Price Performance

Shares of BIB opened at $111.32 on Tuesday. The firm has a market capitalization of $97.96 million, a price-to-earnings ratio of 20.68 and a beta of 1.25. ProShares Ultra Nasdaq Biotechnology has a 1-year low of $73.78 and a 1-year high of $126.40. The company has a 50-day moving average of $113.46 and a 200 day moving average of $96.81.

Shares of ProShares Ultra Nasdaq Biotechnology are scheduled to split on the morning of Thursday, November 19th. The 2-1 split was recently announced. The newly issued shares will be payable to shareholders after the closing bell on Wednesday, November 18th.

Hedge Funds Weigh In On ProShares Ultra Nasdaq Biotechnology

A number of institutional investors have recently modified their holdings of the stock. Toth Financial Advisory Corp purchased a new position in shares of ProShares Ultra Nasdaq Biotechnology during the third quarter worth approximately $118,000. Jump Financial LLC raised its stake in shares of ProShares Ultra Nasdaq Biotechnology by 163.8% during the third quarter. Jump Financial LLC now owns 6,736 shares of the exchange traded fund’s stock valued at $778,000 after acquiring an additional 4,183 shares in the last quarter. Finally, Capital Investment Advisors LLC purchased a new stake in shares of ProShares Ultra Nasdaq Biotechnology in the third quarter valued at approximately $658,000.

ProShares Ultra Nasdaq Biotechnology Company Profile

(Get Free Report)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.

See Also

Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.